MGMT and glioblastoma: In contrast to data obtained from patients with glioblastoma, the methylation level of the MGMT promoter was associated with poorer prognosis or higher chance of relapse after chemo- or radiotherapy in other solid tumors, such as cervical cancer and non-small-cell lung cancer patients with brain metastasis [46,59].